Pune-Based Serum Institute Resumes Covishield Production After Supply Chain Disruption

Pune, 12th April 2023: The Serum Institute of India (SII) has resumed the production of Covishield, the COVID-19 vaccine developed by AstraZeneca and the University of Oxford, after a two-month hiatus due to supply chain disruptions caused by a devastating wave of COVID-19 cases in India.

According to a statement released by the SII, the company has restarted its manufacturing operations and has already produced several million doses of Covishield. The SII is one of the world’s largest vaccine manufacturers and a key supplier of COVID-19 vaccines to India and other countries.